International Myeloma Foundation shared a post on X:
“New FDA approval for relapsed myeloma.
In a major clinical trial, Tec-Dara (teclistamab + daratumumab) reduced the risk of disease progression or death by 83%.
It is now approved for patients whose myeloma has returned after prior treatment.”
Other articles about International Myeloma Foundation on OncoDaily.